Vasovist Magnetic Resonance Angiography (MRA) in Peripheral Arterial Occlusive Disease

Inclusion Criteria: * Patients who have Fontaine-stage III and IV and an indication for therapeutic i.a. DSA * PAOD has to be confirmed by ECCM MRA, CTA, non-selective DSA, Doppler ultrasound (DUS) prior to the study. * Patients who are willing to undergo the study MRA procedure with Vasovist * Patients who are willing to comply with the study procedures (e.g. being followed-up for 12 hours after the Vasovist injection). * Patients who have given their fully informed and written consent voluntarily. Exclusion Criteria: * Being less than 18 years of age. * Women who are pregnant, lactating or who are of childbearing potential and have not had a negative urine pregnancy test the same day as administration of Vasovist. The manufacturer's instructions for performing the urinary pregnancy test are to be followed. * Patients who are scheduled for any therapy between any of the two procedures (MRA and DSA) that interferes with the comparability of the two angiographic procedures. * Having an underlying disease or concomitant medication which may interfere with efficacy or safety evaluations as planned in this study. * Having any physical or mental status that interferes with the informed consent procedure including self-signed consent. * GFR \< 30 ml/m²/1.73m² (MDRD), values ≤ 1 week or patients on hemodialysis * Renal or liver transplant patients, including patients with scheduled liver transplant are excluded due to the potential risk for nephrogenic systemic fibrosis (NSF). * MR contraindications (pacemaker, magnetic clips, severe claustrophobia) * Known allergy to Gadofosveset * Presenting with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents. * Untreated significant stenosis in pelvis * Known severe coagulopathy (PTT \> 25s, Quick \< 60%) * Having received any investigational drug within 7 days prior to entering this study or who are planned to receive any investigational drug during the safety follow-up period. * Not being able to remain lying down for at least 30-45 min (e.g. patients with unstable angina, dyspnea at rest, severe pain at rest, severe back pain). * Being clinically unstable and whose clinical course during the 12 hours observation period is unpredictable. * Being scheduled for, or likely to require, any surgical intervention within 12 hours before or within the follow-up period. * Patients in whom i.a. DSA is contra-indicated preventing him/her from undergoing standard of reference (SOR) procedure. * Close affiliation with the investigational site; e.g. a close relative of the investigator.